Updated version 2 - McKesson and CD&R will privatize infusion therapy service provider Option Care in a $5.8 billion deal.
路透社2026/10/06 12:41Reuters, October 6 – Pharmaceutical distributor McKesson (MCK.N) and private equity firm Clayton Dubilier & Rice (CD&R) reached an agreement on Tuesday to take infusion therapy provider Option Care Health (OPCH.O) private, in a deal valued at approximately $5.8 billions, including debt. The acquisition offer of $32.05 per share represents a 37.1% premium over Option Care's most recent closing price. As a US pharmaceutical distributor, McKesson is seeking to expand its healthcare services portfolio, and this transaction marks its latest move. It also follows the private equity fund’s previous acquisition of another home health service provider, Enhabit. Option Care Health is the largest independent provider of infusion therapy services in the US, serving over 308,000 patients annually through more than 197 service centers, offering home and outpatient infusions, specialty pharmacy, and care for complex conditions. With an aging population and a growing number of patients choosing care outside costly hospital settings, demand for home healthcare in the US continues to increase. Upon closing, CD&R will hold the majority stake, while McKesson will retain a minority interest. Option Care Health will continue to operate as an independent company led by its existing management team. As per transaction terms, McKesson will invest about $1.4 billions to acquire a 49% stake, with the right to acquire CD&R's remaining 51% interest at a later date. According to Michael Cherny, an analyst at Leerink Partners, this deal positions McKesson in line with the trend of healthcare services shifting away from hospitals and medical institutions to alternative sites of care. Additionally, given McKesson’s current operation of Canada’s leading infusion and injection network, Inviva, the transaction extends its reach in the US home infusion market. McKesson’s oncology and multi-specialty business segments, including infusion services, posted revenues of $14.2 billions in the most recent quarter, up 33% year-over-year, benefiting from specialty drug distribution and contributions from acquisitions. The deal is expected to close in the first half of 2027, after which Option Care Health will become a private company.
Added detailed information about ownership and background in the full text
Sneha S K
Reuters, October 6 - Pharmaceutical distributor McKesson (MCK.N) and private equity firm Clayton Dubilier & Rice reached an agreement on Tuesday to take private infusion therapy provider Option Care Health (OPCH.O) in a deal valued at approximately $5.8 billion (including debt).
The acquisition offer of $32.05 per share represents a 37.1% premium to Option Care’s most recent closing price.
As a U.S. pharmaceutical distributor, McKesson has been working to expand its healthcare services portfolio. This deal marks its latest move and also represents another acquisition of a home health services provider by a private equity firm, following Enhabit (link).
Option Care Health is the largest independent infusion therapy provider in the United States, serving more than 308,000 patients annually through over 197 service locations, including home and outpatient infusions, specialty pharmacy, and care for complex conditions.
With an aging population and more patients choosing treatment outside hospitals and other high-cost medical settings, demand for home healthcare continues to grow in the U.S.
After the deal is completed, CD&R will hold a majority stake, while McKesson will hold a minority stake. Option Care Health will continue to operate as an independent company, led by its own management team.
Under the terms of the deal, McKesson will invest approximately $1.4 billion for a 49% stake and retain the right to purchase the remaining 51% stake from CD&R at a future date.
According to a report by Leerink Partners analyst Michael Cherny on Monday evening, the transaction allows McKesson to align with the trend of shifting care delivery from hospitals and health facilities to alternative sites.
In addition, as McKesson currently operates Inviva, Canada's leading infusion and injection network, this deal will further expand its U.S. home infusion service footprint.
McKesson’s oncology and multi-specialty division (including infusion services) generated $14.2 billion in revenue in the latest quarter, up 33% year-over-year, thanks to specialty pharmaceuticals distribution and acquisition contributions.
The deal is expected to close in the first half of 2027, at which point Option Care Health will become a private company.
(For the convenience of non-native English speakers, Reuters has automated the translation of its reports into several other languages. As automated translation may be inaccurate or may not capture the required context, Reuters does not guarantee the accuracy of these automated texts and provides them solely for reader convenience. Reuters accepts no liability for any damage or loss arising from use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Revisit - BUZZ - Preview: PepsiCo expected to report flat earnings per share, investors focus on consumer spending
Republishing the BUZZ report released on Wednesday without modification: October 8 - PepsiCo (PEP.O) shares fell 1.4% on Wednesday, closing at $124.02. The company is set to release its quarterly earnings before the market opens on Thursday, with investors closely watching whether tighter consumer budgets are exerting pressure. According to data from London Stock Exchange Group (LSEG), Wall Street expects the carbonated drinks and snack giant’s third-quarter revenue to rise about 4% year-over-year to $24.96 billion, with adjusted earnings per share (EPS) at $2.29, flat compared to the same period last year. In the previous quarter, PEP’s revenue exceeded expectations, but the company warned that performance in North America would slow due to tighter consumer budgets. Facing cost pressures and the threat from GLP-1 weight loss drugs, PepsiCo is running out of time to meet the growth and profit margin targets set after activist investor Elliott Management invested approximately $4 billion a year ago. (link) So far this year, PEP’s share price has fallen about 14%, underperforming the S&P 500 Soft Drinks & Non-alcoholic Beverages Index (.SPLRCBEVS), which is up about 8%, and the S&P 500 Consumer Staples Index (.SPLRCS), up 6%. The stock’s recent price-earnings ratio is 14, below its five-year average of 21. Among 25 analysts, 7 recommend “strong buy” or “buy”, 17 recommend “hold”, and 1 recommends “sell”. The median target price is $152, down from $170 on July 7. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translations may be inaccurate or may not capture the required context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for readers’ convenience. Reuters accepts no liability for any damage or loss caused by the use of the automated translation feature.)
BUZZ - Jefferies bullish on US cruise sector; Royal Caribbean rises on rating upgrade
October 8th - ** Shares of U.S. cruise company Royal Caribbean (RCL.N) rose 1.2% in pre-market trading to $285.85 ** Jefferies upgraded RCL from "Hold" to "Buy" and raised its price target from $305 to $330 ** The firm also raised its price target for Lindblad Expeditions Holdings (LIND.O) from $29 to $32; LIND shares were flat pre-market ** "We are optimistic about the long-term prospects of the cruise industry as its share in the global vacation market continues to grow," said Jefferies ** The firm noted significant upside in the sector given strong revenue performance ** "We also believe that in the 2027 fiscal year, cruise stocks will be very attractive value investments under various macroeconomic scenarios, with land-based travel products providing additional growth momentum for earnings," Jefferies added ** As of the previous trading day’s close, RCL shares had risen 1.2% and LIND is up 143% year-to-date
Deutsche Bank: Changes in Investor Positions and Capital Flows
New Generation of Crypto Miners Released by ASICID
Crypto prices
More
